ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at D. Boral Capital in a research report issued on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.
A number of other research firms also recently commented on IBRX. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a "strong-buy" rating in a report on Wednesday, October 23rd. BTIG Research began coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a "buy" rating and a $6.00 price objective for the company.
Check Out Our Latest Research Report on IBRX
ImmunityBio Trading Down 1.6 %
ImmunityBio stock traded down $0.05 during midday trading on Monday, hitting $3.08. The stock had a trading volume of 3,461,449 shares, compared to its average volume of 6,437,638. The business has a fifty day moving average price of $3.47 and a 200 day moving average price of $4.06. ImmunityBio has a 12 month low of $2.28 and a 12 month high of $10.53. The stock has a market cap of $2.15 billion, a P/E ratio of -3.35 and a beta of 0.86.
Institutional Trading of ImmunityBio
Large investors have recently modified their holdings of the company. Stephens Inc. AR acquired a new position in ImmunityBio during the 4th quarter valued at about $26,000. Captrust Financial Advisors acquired a new position in shares of ImmunityBio during the third quarter worth approximately $41,000. Mutual Advisors LLC bought a new position in ImmunityBio in the 4th quarter worth approximately $41,000. Virtu Financial LLC acquired a new stake in ImmunityBio in the 3rd quarter valued at approximately $51,000. Finally, Algert Global LLC bought a new stake in ImmunityBio during the 2nd quarter valued at $86,000. Institutional investors and hedge funds own 8.58% of the company's stock.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
